Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rare, Pediatric Drug Development and Reimbursement Boosted In Shaky US Spending Deal

Dec 19 2024

• By Sarah Karlin-Smith

Little girl at doctor's appointment. — Rare and pediatric disease drug development and coverage may get a late 2024 boost from Congress. (Shutterstock)

Related Content

US FDA Seeking New Orphan Products Office Director Amid Internal Moves

Jul 26 2021

US FDA’s Rare Pediatric Voucher Program Faces Tight Deadline For Reauthorization

Sep 04 2024

US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

Oct 05 2024

Life After Chevron: US Supreme Court Ruling Cited In FDA Exclusivity Decision Challenges

Sep 10 2024

Orphan Drug Exclusivity: In Narrow Application Of Catalyst Ruling, FDA Retains Its Existing Regs

Jan 23 2023

US FDA’s Rare Pediatric Voucher Program Faces Tight Deadline For Reauthorization

Sep 04 2024

Pediatric And Rare Disease Drug Development Legislation Clears US House Committee

Sep 19 2024

US FDA Pediatric Priority Review Voucher Renewal May Come With Strings Attached

May 21 2024

FDA Leadership Changes Tune On Pediatric Priority Review Voucher Benefit

Jul 24 2024

Pediatric And Rare Disease Drug Development Legislation Clears US House Committee

Sep 19 2024

Related Companies

Catalyst Pharmaceuticals, Inc.

Jacobus Pharmaceutical Co. Inc

Neurelis, Inc.

Aquestive Therapeutics, Inc.

More from Legislation

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window